Gastroenterology Practice Data for Endoscopy Device Sales
14,000 gastroenterologists, high procedure volumes, and physician-owned ASCs make GI one of the most lucrative specialties for device and pharma vendors.
2026-04-09
The GI Practice Landscape
Gastroenterology is the fourth-largest specialty with roughly 14,000 practitioners. The specialty is heavily procedure-oriented: screening colonoscopies, diagnostic and therapeutic endoscopies, and advanced interventional procedures. GI practices also prescribe expensive biologic therapies for Crohn's, ulcerative colitis, and other IBD.
Three Sales Channels
Endoscopy equipment
Scopes, accessories, AI-assisted polyp detection, and single-use endoscopes. High-volume practices (2,000+ procedures/year) consume significantly more disposables.
Biologic medications
Infliximab, adalimumab, ustekinumab, vedolizumab. GI practices with in-office infusion suites are primary targets. 340B participation changes drug acquisition economics.
ASC products and services
GI has high rates of physician-owned ASCs. Practice-owning GI physicians who also own ASCs control both clinical and purchasing decisions.
Key Data Fields
Practice ownership: Independent, MSO-affiliated (GI Alliance, US Digestive Health, Gastro Health, One GI), or hospital-employed.
ASC ownership: Physician-owned ASCs vs hospital-based outpatient departments.
Procedure volume: High-volume endoscopy practices are the primary equipment targets.
340B status: Hospital-affiliated practices in the 340B program have different biologic economics.
Infusion capability: In-office infusion suites identify biologic pharma targets.
For MSO consolidation targeting, see DSO/MSO guide. Request a sample of GI practice data.
Frequently Asked Questions
How many gastroenterologists practice in the US?
Roughly 14,000, making GI the fourth-largest specialty. Heavily procedure-oriented with significant device and biologic pharma revenue.
What is the GI MSO consolidation trend?
GI Alliance, US Digestive Health, Gastro Health, and One GI are leading platforms. Consolidation changes purchasing authority from individual physicians to platform procurement.
Why does 340B matter for GI pharma?
Hospital-based GI practices in 340B acquire biologics at discounted prices, changing their infusion economics and pharma contracting strategy.
Sources and References
Related Resources
Get the Provider Data You Need
Tell us what you're looking for. We'll build a custom list matched to your target market.
Trusted by healthcare sales teams, medical device companies, and health IT vendors across the US.